Valentina Sarao

14PUBLICATIONS
31CO-AUTHORS
Optical technologyNanomedicineMedical molecular engineering of nucleic acids and proteinsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 06, 2026
Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication.

|Jun 21, 2026
Comment to: Hashiya N, Maruko I, Maruko R et al. Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2026) 264:1611-1617. doi:10.1007/s00417-026-07117-3.

|Feb 25, 2026
AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD.

Daniele Veritti, Valentina Sarao, Asia Amelia Martin

|Jun 02, 2025
Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance.

Daniele Veritti, Valentina Sarao, Paolo Lanzetta

|Apr 01, 2025
Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis.

Valentina Sarao, Daniele Veritti, Francesco Bonini

|Jan 29, 2025
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD.

Daniele Veritti, Valentina Sarao, Paolo Lanzetta

Pageof 3

Frequent Collaborators

14 joint publications

Paolo Lanzetta

12 joint publications

Daniele Veritti

2 joint publications

Jay Chhablani

1 joint publications

Valentina Soppelsa